Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CNTA | US
0.46
3.53%
Healthcare
Biotechnology
30/06/2024
30/08/2024
13.50
13.08
13.66
12.95
Centessa Pharmaceuticals plc a clinical-stage pharmaceutical company discovers develops and delivers medicines to patients. Its pipeline products include SerpinPC an activated protein C inhibitor which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750 an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101 a PD-L1xCD47 LockBody which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292 a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy including TAK-861. In addition its products pipeline comprises CBS001 a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004 a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases as well as earlier-stage preclinical assets including ORX750 an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham the United Kingdom.
View LessPositive Momentum
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
63.4%1 month
72.6%3 months
62.1%6 months
61.9%-
-
5.33
0.30
0.21
1.12
192.70
-
-155.10M
1.53B
1.53B
-
-2.27K
-
-
-55.84
3.35
1.24
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.57
Range1M
5.38
Range3M
6.58
Rel. volume
0.96
Price X volume
5.08M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
NRIX | NRIX | Biotechnology | 25.2 | 1.62B | 0.80% | n/a | 7.77% |
Kura Oncology Inc | KURA | Biotechnology | 21.06 | 1.61B | 2.68% | n/a | 3.59% |
Arcus Biosciences Inc | RCUS | Biotechnology | 17.12 | 1.57B | -1.21% | n/a | 1.73% |
IRON | IRON | Biotechnology | 50.82 | 1.51B | 4.14% | n/a | 0.00% |
Belite Bio Inc | BLTE | Biotechnology | 48.68 | 1.49B | 0.45% | n/a | 0.00% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 21.5 | 1.48B | -0.74% | n/a | 4.89% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 16.42 | 1.48B | 1.99% | n/a | 0.00% |
Dynavax Technologies Corporation | DVAX | Biotechnology | 11.22 | 1.47B | -0.36% | 86.31 | 39.71% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 15.17 | 1.46B | 1.88% | n/a | 53.59% |
Ardelyx Inc | ARDX | Biotechnology | 6.18 | 1.45B | 0.82% | n/a | 71.36% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REV Group Inc | REVG | Recreational Vehicles | 31.84 | 1.65B | 1.69% | 7.49 | 66.74% |
Steelcase Inc | SCS | Building Products & Equipment | 14.14 | 1.61B | 1.87% | 18.36 | 69.98% |
Janus International Group Inc. | JBI | Building Products & Equipment | 10.99 | 1.60B | 0.92% | 12.35 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 7.07 | 1.27B | 0.43% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.74 | 1.17B | -2.65% | n/a | 0.00% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 21.94 | 990.13M | 0.14% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 36.37 | 743.39M | 4.66% | n/a | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.25 | 722.36M | 0.32% | 56.82 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 23.91 | 621.28M | 1.18% | 14.94 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.12 | 0.97 | Par |
Ent. to Revenue | 192.70 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 5.33 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 62.14 | 76.13 | Par |
Debt to Equity | 0.30 | -2.05 | Expensive |
Debt to Assets | 0.21 | 0.25 | Par |
Market Cap | 1.53B | 4.04B | Emerging |